Ideaya Biosciences Inc. Enrolls First Patient in Phase 1 Trial of IDE574

Date of Announcement: 6 April 2026Source: PR Newswire (www.prnewswire.com )

Clinical Development Milestone

Ideaya Biosciences Inc. (NASDAQ: IDYA) announced that the first patient has been enrolled in a Phase 1 dose‑escalation trial evaluating IDE574, a potential first‑in‑class oral small‑molecule inhibitor targeting both lysine acetyltransferase 6 (KAT6) and lysine acetyltransferase 7 (KAT7). The trial will assess safety, tolerability, pharmacokinetics, and preliminary efficacy of IDE574 as a monotherapy in patients with solid tumours, including breast, prostate, colorectal, and lung cancer.

Rationale for Targeting KAT6/7

  • Dual Inhibition: IDE574 is described as a selective, equipotent dual inhibitor of KAT6 and KAT7.
  • Potency and Selectivity: The compound exhibits single‑digit to low‑teens nanomolar cellular potency in target‑engagement assays for KAT6 and KAT7, and shows approximately 350‑ to 2 000‑fold selectivity over the paralogs KAT5 and KAT8.
  • Preclinical Efficacy: In pre‑clinical models (both cell‑derived xenografts and patient‑derived xenografts), the dual inhibitor demonstrates superior monotherapy efficacy and durability compared with KAT6‑selective agents.
  • Combination Potential: IDE574 may be combined with other agents in Ideaya’s proprietary pipeline, offering multiple therapeutic opportunities.

Presentation at AACR 2026

The company will present the pre‑clinical profile of IDE574 at the American Association for Cancer Research (AACR) meeting in South San Francisco, California, scheduled for April 2026.

Company Context

Ideaya Biosciences Inc. focuses on oncology therapeutics, developing biology and small‑molecule drugs for cancer treatment. The firm’s market capitalization is approximately 2.88 billion USD, and its share price as of 1 April 2026 closed at $32.74. The company’s price‑earnings ratio is negative, reflecting its early‑stage development status.

Additional reporting on the enrollment was provided by German‑language and English‑language financial news outlets on 6 April 2026, summarising the same milestone without additional data.